| Name | TT-10 |
| Description | TT-10 (TAZ-K), an activator of YES-associated protein (YAP)-transcriptional enhancer factor domain (TEAD) activity, has potential application in heart disease research, specifically for conditions characterized by loss of cardiomyocytes. |
| In vitro | TT-10 (10 μmol/L ; 48 h) significantly promoted cell cycle activation and cell division of human induced pluripotent stem cell (hiPSC) derived cardiomyocytes (hiPSCM).[1] |
| In vivo | TT-10 (2 μM, 10 μM, 20 μM, or 100 μM ; 48 h ; intraperitoneal injections) was administered to infarcted mouse hearts, the treatment promoted cardiomyocyte proliferation and was associated with declines in infarct size 1 week after administration, but cardiac function worsened at later time points.[2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 60 mg/mL (211.75 mM), Sonication is recommended. 2% DMSO+40% PEG300+5% Tween 80+53% Saline : 1.25 mg/mL (4.41 mM)
|
| Keywords | YAP–TEAD | TT-10 | TT10 | TT 10 |
| Inhibitors Related | AICAR | MY-1076 | YAP-TEAD-IN-3 | Verteporfin | DC-TEADin02 | MSC-4106 | OPN-9652 | VT107 | PY-60 | VT104 | MYF-01-37 | Ki16425 |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Stem Cell Differentiation Compound Library | Anti-Cardiovascular Disease Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |